PRESS RELEASE N 22/2018 of 04 October 2018

MOLOGEN presenting final results from the randomized phase II IMPULSE study at ESMO 2018

Berlin, 04 October 2018 - The biopharmaceutical company MOLOGEN AG will present a poster at the ESMO 2018 Congress (EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY) in Munich, Germany (19 - 23 October 2018). The poster is featuring final data of the exploratory phase II IMPULSE study in extensive-stage small cell lung cancer (ES-SCLC). Additionally, these data are also being published in the high-ranking, peer-reviewed journal of the European Society of Medical Oncology: Annals of Oncology.

Abstract details:
Abstract number: 1672P
Title: "Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small cell lung cancer (ES-SCLC): Final results from the randomized phase 2 IMPULSE study"

Presentation: The Poster Session will take place on Saturday, 20 October 2018, 12:30 p.m.-13:30 p.m. in Hall A3 - Poster Area Networking Hub

For more information on ESMO 2018 please visit the website:

MOLOGEN AG
MOLOGEN AG is a biopharmaceutical Company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases. The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead compound lefitolimod and the next-generation molecule family EnanDIM^(R).

The immunotherapeutic agent lefitolimod is the Company's lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in small cell lung cancer have been announced in April 2017, and the final analysis in the first quarter 2018 confirmed the data. Furthermore, data from the extension phase of the TEACH study in HIV have also been published in 2017. In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy^(R)) in various cancer indications.
Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.

MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange.

Contact

Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: 7 88 - 38
Fax: 7 88 - 50

Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.